3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
2
Plasma cell
1
Dermatologic
1
Conditions
Lymphoma, T-Cell, Cutaneous
13
Mycosis Fungoides
10
Sezary Syndrome
9
Lymphoma, Non-Hodgkin
8
Precursor Cell Lymphoblastic Leukemia-Lymphoma
6
Lymphoma, Large-Cell, Anaplastic
6
Lymphoma, Follicular
6
Lymphoma
6
Leukemia, Lymphocytic, Chronic, B-Cell
6
Immunoblastic Lymphadenopathy
6
Hodgkin Disease
6
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
5
Lymphoma, Mantle-Cell
5
Lymphoma, Large-Cell, Immunoblastic
5
Lymphoma, Large B-Cell, Diffuse
5
Lymphoma, B-Cell, Marginal Zone
5
Burkitt Lymphoma
5
Waldenstrom Macroglobulinemia
4
Uveal Melanoma
3
Multiple Myeloma
3
Melanoma
3
Lymphoma, T-Cell, Peripheral
3
Lymphoma, T-Cell
3
Lymphoma, Extranodal NK-T-Cell
3
Leukemia, Hairy Cell
3
Intraocular Lymphoma
3
Subcutaneous panniculitis-like T-cell lymphoma
2
Prostatic Neoplasms
2
Neoplasms
2
Leukemia, Myeloid, Acute
2
Interventions
cobomarsen
2
pimonidazole
1
fludarabine
1
Vorinostat
1
Bendamustine Hydrochloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Immune System Diseases
×
Vorinostat
×
Dermatologic
×
Clear all
NCT03713320
2022-04-08
SOLAR
miRagen Therapeutics, Inc.
Phase 2
Terminated
37 enrolled
23 charts